Compare · RVMD vs SCNI
RVMD vs SCNI
Side-by-side comparison of Revolution Medicines Inc. (RVMD) and Scinai Immunotherapeutics Ltd. (SCNI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RVMD and SCNI operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $39.58B, about 31601.9x SCNI ($1.3M).
- Over the past year, RVMD is up 384.6% and SCNI is down 88.8% - RVMD leads by 473.5 points.
- RVMD has hit the wire 3 times in the past 4 weeks while SCNI has been quiet.
- RVMD has more recent analyst coverage (25 ratings vs 0 for SCNI).
- Company
- Revolution Medicines Inc.
- Scinai Immunotherapeutics Ltd.
- Price
- $186.14+3.91%
- $0.24-7.73%
- Market cap
- $39.58B
- $1.3M
- 1M return
- +18.88%
- -27.96%
- 1Y return
- +384.61%
- -88.84%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2015
- News (4w)
- 3
- 0
- Recent ratings
- 25
- 0
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest RVMD
- European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process
- Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
- Director Patel Sushil exercised 2,955 shares at a strike of $37.54 and sold $1,048,967 worth of shares (5,580 units at $187.99) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 21,656 units (SEC Form 4)
- Chief Financial Officer Anders Jack exercised 20,000 shares at a strike of $18.56 and sold $3,366,604 worth of shares (20,000 units at $168.33) as part of a pre-agreed trading plan (SEC Form 4)
- Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
- Director Kim Lorence H. was granted 1,191 shares, increasing direct ownership by 2% to 74,281 units (SEC Form 4)
- Director Borisy Alexis was granted 1,191 shares, increasing direct ownership by 0.05% to 2,340,075 units (SEC Form 4)
- Director Anderson Elizabeth M was granted 1,191 shares, increasing direct ownership by 14% to 9,406 units (SEC Form 4)
- Director Horning Sandra was granted 1,191 shares, increasing direct ownership by 1% to 97,765 units (SEC Form 4)
- Director Clyburn Frank was granted 1,191 shares, increasing direct ownership by 12% to 10,929 units (SEC Form 4)
Latest SCNI
- Director Germain Mark was granted 120,000,000 units of Ordinary Shares (SEC Form 4)
- Chief Executive Officer Reichman Amir was granted 400,000,000 units of Ordinary Shares, increasing direct ownership by 128% to 711,637,600 units (SEC Form 4)
- SEC Form 6-K filed by Scinai Immunotherapeutics Ltd.
- SEC Form 6-K filed by Scinai Immunotherapeutics Ltd.
- Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives
- SEC Form 6-K filed by Scinai Immunotherapeutics Ltd.
- Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility
- SEC Form EFFECT filed by Scinai Immunotherapeutics Ltd.
- SEC Form 424B3 filed by Scinai Immunotherapeutics Ltd.
- Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe